

Curtis R Brandt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11248406/publications.pdf>

Version: 2024-02-01

79
papers

1,999
citations

236925

25
h-index

302126

39
g-index

80
all docs

80
docs citations

80
times ranked

1954
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of Influenza Virus Infection by a Novel Antiviral Peptide That Targets Viral Attachment to Cells. <i>Journal of Virology</i> , 2006, 80, 11960-11967.	3.4	143
2	In vitro localization of TIGR/MYOC in trabecular meshwork extracellular matrix and binding to fibronectin. <i>Investigative Ophthalmology and Visual Science</i> , 2002, 43, 151-61.	3.3	94
3	Evidence for an Interaction of Herpes Simplex Virus with Chondroitin Sulfate Proteoglycans during Infection. <i>Virology</i> , 1995, 208, 531-539.	2.4	89
4	Using HSV-1 Genome Phylogenetics to Track Past Human Migrations. <i>PLoS ONE</i> , 2013, 8, e76267.	2.5	76
5	The role of viral and host genes in corneal infection with herpes simplex virus type 1. <i>Experimental Eye Research</i> , 2005, 80, 607-621.	2.6	71
6	The effect of C3 transgene expression on actin and cellular adhesions in cultured human trabecular meshwork cells and on outflow facility in organ cultured monkey eyes. <i>Molecular Vision</i> , 2005, 11, 1112-21.	1.1	65
7	Herpes Simplex Virus Mediated Gene Transfer to Primate Ocular Tissues. <i>Experimental Eye Research</i> , 1999, 69, 385-395.	2.6	58
8	Isolation and partial characterization of an antiviral, RC-183, from the edible mushroom <i>Rozites caperata</i> . <i>Antiviral Research</i> , 1999, 43, 67-78.	4.1	53
9	The HSV-1 UL45 18 kDa gene product is a true late protein and a component of the virion. <i>Virus Research</i> , 1993, 29, 167-178.	2.2	48
10	Multiple Peptides Homologous to Herpes Simplex Virus Type 1 Glycoprotein B Inhibit Viral Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 987-996.	3.2	48
11	The HSV-1 UL45 gene product is not required for growth in vero cells. <i>Virology</i> , 1991, 185, 419-423.	2.4	46
12	Genomic, Phylogenetic, and Recombinational Characterization of Herpes Simplex Virus 2 Strains. <i>Journal of Virology</i> , 2015, 89, 6427-6434.	3.4	45
13	Modified FGF4 Signal Peptide Inhibits Entry of Herpes Simplex Virus Type 1. <i>Journal of Virology</i> , 2001, 75, 2634-2645.	3.4	44
14	Recombination Analysis of Herpes Simplex Virus 1 Reveals a Bias toward GC Content and the Inverted Repeat Regions. <i>Journal of Virology</i> , 2015, 89, 7214-7223.	3.4	44
15	Evaluation of a β -Defensin in a Murine Model of Herpes Simplex Virus Type 1 Keratitis. , 2007, 48, 5118.		43
16	HSV-1 Vector-Delivered FGF2 to the Retina Is Neuroprotective but Does Not Preserve Functional Responses. <i>Molecular Therapy</i> , 2001, 3, 746-756.	8.2	39
17	A Quantitative Rabbit Model of Vaccinia Keratitis. , 2010, 51, 4531.		39
18	Peptides Containing Membrane-transiting Motifs Inhibit Virus Entry. <i>Journal of Biological Chemistry</i> , 2002, 277, 36018-36023.	3.4	38

#	ARTICLE	IF	CITATIONS
19	Multiplex Sequencing of Seven Ocular Herpes Simplex Virus Type-1 Genomes: Phylogeny, Sequence Variability, and SNP Distribution. , 2011, 52, 9061.		38
20	Gene Therapy Targeting Glaucoma: Where Are We?. Survey of Ophthalmology, 2009, 54, 472-486.	4.0	36
21	Renin mRNA is synthesized locally in rat ocular tissues. Current Eye Research, 1994, 13, 755-763.	1.5	35
22	A murine model of herpes simplex virus-induced ocular disease for antiviral drug testing. Journal of Virological Methods, 1992, 36, 209-222.	2.1	34
23	Gene therapy for glaucoma: treating a multifaceted, chronic disease. Investigative Ophthalmology and Visual Science, 2002, 43, 2513-8.	3.3	32
24	Inhibition of Herpes Simplex Virus Type 1 Infection by Cationic \hat{I}^2 -Peptides. Antimicrobial Agents and Chemotherapy, 2008, 52, 2120-2129.	3.2	31
25	Phylogenetic and recombination analysis of the herpesvirus genus varicellovirus. BMC Genomics, 2017, 18, 887.	2.8	31
26	Quantitative Trait Locus Based Virulence Determinant Mapping of the HSV-1 Genome in Murine Ocular Infection: Genes Involved in Viral Regulatory and Innate Immune Networks Contribute to Virulence. PLoS Pathogens, 2016, 12, e1005499.	4.7	30
27	Evaluation of Therapeutic Interventions for Vaccinia Virus Keratitis. Journal of Infectious Diseases, 2011, 203, 683-690.	4.0	28
28	Enhanced Inhibition of Herpes Simplex Virus Type 1 Growth in Human Corneal Fibroblasts by Combinations of Interferon- \hat{A} and - \hat{A} . Journal of Infectious Diseases, 1992, 166, 1401-1402.	4.0	27
29	Multiple Determinants Contribute to the Virulence of HSV Ocular and CNS Infection and Identification of Serine 34 of the US1 Gene as an Ocular Disease Determinant. , 2003, 44, 2657.		27
30	Corneal Toxicity of Cell-Penetrating Peptides That Inhibit Herpes simplex Virus Entry. Journal of Ocular Pharmacology and Therapeutics, 2006, 22, 279-289.	1.4	27
31	Sialic Acid on Herpes Simplex Virus Type 1 Envelope Glycoproteins Is Required for Efficient Infection of Cells. Journal of Virology, 2007, 81, 3731-3739.	3.4	27
32	H-1152 Effects on Intraocular Pressure and Trabecular Meshwork Morphology of Rat Eyes. Journal of Ocular Pharmacology and Therapeutics, 2008, 24, 373-379.	1.4	27
33	Plasmid mediated mutagenesis of a cellular gene in transfected eukaryotic cells. Nucleic Acids Research, 1987, 15, 561-573.	14.5	25
34	The effect of viral inoculum level and host age on disease incidence, disease severity, and mortality in a murine model of ocular HSV-1 infection. Current Eye Research, 1995, 14, 145-152.	1.5	24
35	Addition of a C-Terminal Cysteine Improves the Anti-Herpes Simplex Virus Activity of a Peptide Containing the Human Immunodeficiency Virus Type 1 TAT Protein Transduction Domain. Antimicrobial Agents and Chemotherapy, 2007, 51, 1596-1607.	3.2	23
36	Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine. Vaccine, 2011, 29, 7696-7703.	3.8	22

#	ARTICLE	IF	CITATIONS
37	Peptide Therapeutics for Treating Ocular Surface Infections. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 691-699.	1.4	21
38	Genomic, Recombinational and Phylogenetic Characterization of Global Feline Herpesvirus 1 Isolates. Virology, 2018, 518, 385-397.	2.4	21
39	Identification of the Minimal Active Sequence of an Anti-Influenza Virus Peptide. Antimicrobial Agents and Chemotherapy, 2011, 55, 1810-1813.	3.2	20
40	A Cationic Peptide, TAT-Cd0, Inhibits Herpes Simplex Virus Type 1 Ocular Infection In Vivo. , 2013, 54, 1070.		20
41	Prospects for Lentiviral Vector Mediated Prostaglandin F Synthase Gene Delivery in Monkey Eyes<i>In vivo</i>. Current Eye Research, 2014, 39, 859-870.	1.5	20
42	Rapid small-scale isolation of herpes simplex virus DNA. Journal of Virological Methods, 1994, 48, 189-196.	2.1	19
43	Mapping Murine Corneal Neovascularization and Weight Loss Virulence Determinants in the Herpes Simplex Virus 1 Genome and the Detection of an Epistatic Interaction between the UL and IRS/US Regions. Journal of Virology, 2016, 90, 8115-8131.	3.4	17
44	Tyrosine 116 of the Herpes Simplex Virus Type 1 IE α 22 Protein Is an Ocular Virulence Determinant and Potential Phosphorylation Site. , 2003, 44, 4601.		16
45	Ocular Distribution, Spectrum of Activity, and <i>In Vivo</i> Viral Neutralization of a Fully Humanized Anti-Herpes Simplex Virus IgG Fab Fragment following Topical Application. Antimicrobial Agents and Chemotherapy, 2012, 56, 1390-1402.	3.2	16
46	Antiviral activity of the EB peptide against zoonotic poxviruses. Virology Journal, 2012, 9, 6.	3.4	15
47	Treatment of Spontaneously Arising Retinoblastoma Tumors in Transgenic Mice with an Attenuated Herpes Simplex Virus Mutant. Virology, 1997, 229, 283-291.	2.4	14
48	Ocular drug delivery: molecules, cells, and genes. Canadian Journal of Ophthalmology, 2007, 42, 447-454.	0.7	13
49	Viral Vector Effects on Exoenzyme C3 Transferase-Mediated Actin Disruption and on Outflow Facility. , 2015, 56, 2431.		12
50	Virulence genes in herpes simplex virus type 1 corneal infection. Current Eye Research, 2004, 29, 103-117.	1.5	11
51	Induction of interleukin-6 in human retinal epithelial cells by an attenuated Herpes simplex virus vector requires viral replication and NF κ B activation. Experimental Eye Research, 2008, 86, 178-188.	2.6	10
52	Sequence Variation in the Herpes Simplex Virus US1 Ocular Virulence Determinant. , 2011, 52, 4630.		10
53	Transformation of human trabecular meshwork cells with SV40 TAg alters promoter utilization. Current Eye Research, 2002, 25, 347-353.	1.5	9
54	The Virucidal EB Peptide Protects Host Cells from Herpes Simplex Virus Type 1 Infection in the Presence of Serum Albumin and Aggregates Proteins in a Detergent-Like Manner. Antimicrobial Agents and Chemotherapy, 2010, 54, 4275-4289.	3.2	9

#	ARTICLE	IF	CITATIONS
55	Toll-like receptors 4, 5, 6 and 7 are constitutively expressed in non-human primate retinal neurons. Journal of Neuroimmunology, 2018, 322, 26-35.	2.3	9
56	Mixed ocular infections identify strains of herpes simplex virus for use in genetic studies. Journal of Virological Methods, 1991, 35, 127-135.	2.1	8
57	IFN- α induces MxA gene expression in cultured human corneal fibroblasts. Experimental Eye Research, 1995, 60, 137-142.	2.6	8
58	Ocular drug delivery: Molecules, cells, and genes. Canadian Journal of Ophthalmology, 2007, 42, 447-454.	0.7	8
59	Proteasome Inhibition Increases the Efficiency of Lentiviral Vector-Mediated Transduction of Trabecular Meshwork. , 2018, 59, 298.		8
60	Susceptibility of +/+, +/- and nu/nu BALB/c Mice to Ocular Herpes simplex Virus Infection. Ophthalmic Research, 1992, 24, 332-337.	1.9	7
61	Oligonucleotides designed to inhibit TLR9 block Herpes simplex virus type 1 infection at multiple steps. Antiviral Research, 2014, 109, 83-96.	4.1	7
62	Primate neural retina upregulates IL-6 and IL-10 in response to a herpes simplex vector suggesting the presence of a pro-/anti-inflammatory axis. Experimental Eye Research, 2016, 148, 12-23.	2.6	7
63	Ocular drug delivery: molecules, cells, and genes. Canadian Journal of Ophthalmology, 2007, 42, 447-54.	0.7	6
64	Heterogeneity of Type I Collagen Expression in Human Corneal Keratoconus Fibroblasts. Ophthalmic Research, 1993, 25, 273-279.	1.9	5
65	Evaluation of the antitumor effects of Herpes simplex virus lacking ribonucleotide reductase in a murine retinoblastoma model. Current Eye Research, 2004, 29, 167-172.	1.5	5
66	Ocular Immunopathology. Molecular and Integrative Toxicology, 2017, , 695-762.	0.5	5
67	Genomic nucleotide-based distance analysis for delimiting old world monkey derived herpes simplex virus species. BMC Genomics, 2020, 21, 436.	2.8	5
68	Effect of a Soluble Epoxide Hydrolase Inhibitor, UC1728, on LPS-Induced Uveitis in the Rabbit. Journal of Ocular Biology, 2016, 4, .	0.4	5
69	Interferon- α and Interferon- β Induced Modulation of Proteins in Human Corneal Fibroblasts. Journal of Interferon Research, 1993, 13, 289-294.	1.2	4
70	Glaucoma gene therapy. Expert Review of Ophthalmology, 2007, 2, 227-236.	0.6	4
71	A Cationic TAT Peptide Inhibits Herpes Simplex Virus Type 1 Infection of Human Corneal Epithelial Cells. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 541-547.	1.4	4
72	Knockdown of TRIM5 α or TRIM11 increases lentiviral vector transduction efficiency of human Muller cells. Experimental Eye Research, 2021, 204, 108436.	2.6	3

#	ARTICLE	IF	CITATIONS
73	Rapid in vivo isolation of gene expression elements using an HSV amplicon system. Journal of Virological Methods, 2003, 113, 1-12.	2.1	2
74	Enhanced isolation of low frequency herpes simplex virus recombinants using green-fluorescent protein and FACS. Journal of Virological Methods, 2004, 115, 73-81.	2.1	2
75	A Mouse Model of Multi-Drug Resistant Staphylococcus aureus-induced Ocular Disease. Journal of Ocular Biology, 2016, 4, .	0.4	2
76	Thymidine Kinase and Susceptibility to Interferon Are Not Involved in the Increased Virulence of Recombinant Viruses Isolated following Mixed Ocular Infection with HSV Strains OD4 and CJ394. Ophthalmic Research, 1996, 28, 125-129.	1.9	1
77	Influenza defense: expanding our arsenal with peptide antivirals. Future Virology, 2007, 2, 231-233.	1.8	1
78	Ribonucleotide Reductase and the Ocular Virulence of Herpes Simplex Virus Type 1. Frontiers of Virology, 1994, , 136-150.	0.6	1
79	Progress and Prospects in Ocular Gene Therapy. , 2008, , 393-420.		0